Considered a class effect that affects anywhere from 5-90% of adult patients treated with MEK/BRAF inhibitors based on published reports (51), retinopathy can present with symptomatic blurry vision, floaters, or photophobia, and most severely, may result in retinal detachment or retinal vein occlusion. This evidence concerns the gene MAP2K7 and retinal disorder.